Belite Bio, Inc. · NASDAQ:BLTE
Belite Bio — Q3 2025 Earnings Presentation
7 slides from Belite Bio's earnings presentation, Nov 10, 2025
Slide 1: Q3 2025 Financial Results Conference Call
Q3 2025 Financial Results Conference Call November 10, 2025, 4:30 p.m. ET Nasdaq: BLTE For more info please visit: www.belitebio.com
Slide 2: Experienced Leadership Team
Experienced Leadership Team Belite Management Team Tom Lin, MMED, PhD, MBA Hendrik Scholl, MD, MA Nathan Mata, PhD Hao-Yuan Chuang, CFA, MBA, FRM (Chairman, CEO) (CMO) (CSO) (CFO) • 10+ years of executive management • 25+ years of expertise in treating retinal • 15+ years of ophthalmic drug • 13+ ye
Slide 3: Forward-Looking Statements and Legal Disclaimer
Forward-Looking Statements and Legal Disclaimer This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire,
Slide 4: Belite Bio Pipeline Overview
Belite Bio Pipeline Overview PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NDA Stargardt Disease (STGD1) • Ph2, 24-month final data continues to show slowing of lesion growth • Ph3, 2-year treatment, global trial (“DRAGON” Study) completed (104 subjects, age 12-20, topline data expected Q4 2025) Tinlarebant •
Slide 5: Q3 2025 Financial Results
Q3 2025 Financial Results For more info please visit: www.belitebio.com
Slide 6: 2025 Third-Quarter Financial Results
2025 Third-Quarter Financial Results (In thousand USD) For the Three Months Ended September 30 2024 2025 Total operating expenses 9,740 23,018 - R&D 6,842 10,307 - G&A 2,898 12,711 Net loss (8,679) (21,690) • Cash, liquidity fund, time deposits and U.S. treasury bills: $275.6 million • Total operati
Slide 7: Q&A
Q&A For more info please visit: www.belitebio.com